CN106265702A - Acarbose medicine composition and preparation method thereof - Google Patents
Acarbose medicine composition and preparation method thereof Download PDFInfo
- Publication number
- CN106265702A CN106265702A CN201610675348.XA CN201610675348A CN106265702A CN 106265702 A CN106265702 A CN 106265702A CN 201610675348 A CN201610675348 A CN 201610675348A CN 106265702 A CN106265702 A CN 106265702A
- Authority
- CN
- China
- Prior art keywords
- acarbose
- medicine composition
- prescription
- pregelatinized starch
- microcrystalline cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Abstract
The invention discloses a kind of Acarbose medicine composition and preparation method thereof.There is the easy moisture absorption in current Precose and disintegrate slowly and prepares the defects such as difficulty.The Acarbose medicine composition of the present invention, by weight, including acarbose 1 part, filler 14 parts, lubricant 0.001 0.005 parts, fluidizer 0.005 0.01 parts；Described filler includes microcrystalline Cellulose and pregelatinized Starch；First by acarbose with there is the pregelatinized Starch of good fluidity to carry out first order mixing, then carry out the second level with remaining filler and mix, be eventually adding lubricant and fluidizer carries out third level mixing.The Acarbose medicine composition of the present invention, without disintegrating agent, rely in pregelatinized Starch and microcrystalline Cellulose adjuvant characteristic own with disintegrative or help and collapse effect and make product reach disintegrating property.The present invention uses stepped mixing powder vertical compression technique to reach product quality requirement, and technique is simple, is suitable for large-scale production.
Description
Technical field
The invention belongs to field of pharmaceutical preparations, a kind of pharmaceutical composition containing acarbose and preparation thereof
Method.
Background technology
Acarbose (Acarbose), be Bayer A.G 70 noon for the one developed mid-term for treating II type
The medicine of diabetes, is now the number one brand medicine of oral antidiabetic drug.Its chemistry is entitled: O-4,6-double deoxidation-4-[[(1S, 4R,
5S, 6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexenyl group-1-base] amino]-α-D-glucopyranosyl-(1 →
4)-O-α-D-Glucopyranose .-(1 → 4)-D-Glucopyranose., nineteen ninety take the lead in Germany list, within 1996 years, obtain FDA approval
Listing in the U.S., within 1998, acarbose enters China, trade name " acarbose ".Structural formula is as follows:
Acarbose is mainly used in the treatment of type Ⅱdiabetes mellitus.Competitive inhibition glycoside hydrolytic enzyme in intestinal.Press down
The α glucosidase of small intestinal processed, many sugar decomposition of suppression food, make the absorption of sugar slow down accordingly, thus reduce postprandial hyperglycemia,
Coordinate Diet Therapy diabetes.NIDDM (non-insulin-dependent diabetes mellitus) can share with other oral medicines, to IDDM
(insulin dependent diabetes mellitus (IDDM)) patient also can apply with insulin combination, effectively to control diabetes.
The dosage form used clinically at present is tablet and capsule, and the instructions of taking of tablet is for the most at once to take.Due to
The particularity of acarbose physical property, the easy moisture absorption of acarbose tablet is hardening, so the characteristic of raw material need to be overcome, screening optimum
Ratio of adjuvant and preparation technology.
The conventional preparation method of tablet at present:
Wet granulation: disintegration of tablet can be caused to delay with traditional wet granulation technology, dissolution is slack-off.Wet granulation adds
Easilying lead to the tablet moisture absorption after entering disintegrating agent increase, after sample long-term storage, disintegrate postpones.
Dry granulation: inherently need the biggest squeeze pressure because dry granulation is pressed into sheet cake, be added without disintegrate at tablet
In the case of agent, after dry granulation, tabletting is easily caused the reduction of disintegration of tablet performance again, it is difficult to disintegrate.Dry granulation once becomes itself
Product rate is relatively low, and fine powder also needs to again enter dry granulating machine and suppresses, and causes the production time long, and operation is loaded down with trivial details, is not suitable for big
Production is carried out.
Powder vertical compression: as used powder vertical compression technique, need again adjuvant to have good mobility and mouldability, its adjuvant
The preparation section of selection, proportioning and technique needs to grope and optimize.
The patent documentation of existing Precose (not comprising oral cavity disintegration tablet, chewable tablet, slow releasing tablet and compound preparation) is as follows:
Authorization Notice No. is that the Chinese patent of CN100464754C discloses a kind of Acarbose medicine composition and system thereof
Preparation Method, described Acarbose medicine composition includes acarbose, filler and lubricant, and this compositions can be made into sheet
Agent.This patent is preferred by concrete adjuvant, does not contains PVP, overcomes the defect of the easy moisture absorption of original tablet, has good simultaneously
Preparation performance.This invention additionally provides a kind of method preparing this tablet, the most first by acarbose and the profit having fluidizer effect
Lubrication prescription mixes, and adds filler, add mix lubricant after mixing, tabletting, meets the system of pharmaceutical criteria to guarantee to make
Agent.
The patent documentation of Application No. 201210193601.X discloses a kind of acarbose oral solid formulation compositions
And preparation method thereof, described acarbose oral solid formulation compositions is made up of acarbose, filler and lubricant, its powder
End mobility and compressibility all improve a lot, and the solid preparation hygroscopicity prepared is lower, and stability is more preferable, have good
Prospects for commercial application.
The patent of Application No. 201310232803.5 discloses a kind of acarbose tablet and preparation method thereof, by A Kabo
Sugar, microcrystalline Cellulose and starch, 2/3 carboxymethylstach sodium mix homogeneously, obtain pre-composition；By said mixture by dry method system
Grain, granulate, obtain particulate matter；By above-mentioned particulate matter, 1/3 carboxymethylstach sodium, magnesium stearate and silicon dioxide mix homogeneously, warp
Tabletting machine, obtains acarbose tablet.The tablet that the method uses compressing dry granulation to prepare is effectively improved tablet
Hardness and stability, solve that disintegration is defective, the underproof problem of microorganism, thus improves product quality, and technique
Flow process is simple, saves the energy, cost-effective, is suitable for industrialized production.
The patent documentation of Application No. 201510459296.8 discloses a kind of Acarbose medicine composition and preparation thereof
Method, specially acarbose tablet, its prescription consists of filler one or several in Lactis Anhydrous, low moisture starch
Kind.Relative to prior art, this invention is by the kind of adjuvant in screening tablet, it is provided that the simple preparation technology of a kind of employing
I.e. can reach that preparation moisture is low, be difficult to moisture absorption and possess the Acarbose medicine composition of certain humidity resistance, good stability.Should
Product stability prepared by method is good, and the stability of projects index such as tablet appearance, impurity is significantly better than Bayer commercially available prod
Acarbose, and the preparation technology that the method provides is simple, easily-controllable, production efficiency is high, energy consumption is low.
Summary of the invention
The technical problem to be solved is the defect such as overcome the above-mentioned easy moisture absorption of existing tablet and disintegrate slow, it is provided that one
Kind without disintegrating agent and the Acarbose medicine composition that is suitable for powder vertical compression piece agent, during to prevent this medicine from making tablet because of
The moisture absorption causes disintegrate phenomenon slowly to occur, it is to avoid affect curative effect of medication.
To this end, the present invention adopts the following technical scheme that: Acarbose medicine composition, by weight, including:
Described filler includes microcrystalline Cellulose and pregelatinized Starch.
The Acarbose medicine composition of the present invention, without disintegrating agent, relies on pregelatinized Starch and microcrystalline Cellulose itself auxiliary
In material characteristic with disintegrative or help and collapse effect and make product reach disintegrating property.
The Acarbose medicine composition powder vertical compression of the present invention makes tablet, and its disintegrative and dissolution reach standard,
And prevent the easy moisture absorption of tablet to cause the reduction of disintegrating property.
Further, described lubricant is one or more in magnesium stearate, stearic acid or hydrogenated vegetable oil.
Further, described fluidizer is silicon dioxide or Pulvis Talci.
Further, it is contemplated that patient takes acarbose convenience, single dose weight is unsuitable excessive, and additionally starch based is auxiliary
Material hydrolysis also will produce glucose, so the adjuvant amount that should reduce in prescription as far as possible, the weight portion of filler is 1.5-2 part, its
Middle microcrystalline Cellulose 0.5 part, pregelatinized Starch 1-1.5 part.
Further, with the mobility (angle of repose) of powder after mixing and the hardness of tablet, friability, disintegration time,
Weight differential, content, have related substance, dissolution as inspection target, prescription to be screened, obtain following be more highly preferred to fill out
Fill agent combination: the weight portion of described filler is 1.6-1.8 part, wherein microcrystalline Cellulose 0.5 part, pregelatinized Starch 1.1-1.3
Part.
Further, the weight portion of described lubricant is most preferably 0.002 part.
Further, the weight portion of described fluidizer is most preferably 0.007 part.
The preparation method of above-mentioned Acarbose medicine composition, it uses stepped mixing technique: first by acarbose with have
The pregelatinized Starch of good fluidity carries out first order mixing, then carries out the second level with microcrystalline Cellulose and mix, and is eventually adding profit
Lubrication prescription and fluidizer carry out third level mixing, tabletting.After mixing, drug content uniformity reaches standard-required, and thing mobility is stopped
Angle, between 32～34 °, meets the tabletting requirement of tablet, and tablet weight variation controls ± 3%.
The preparation method that the present invention provides, with short production cycle, material loss is little, meanwhile, material open-assembly time in atmosphere
Also shorten, thus be more suitable for industrialization, and better assure that the quality of finished product.
The method preparing Acarbose medicine composition that the present invention provides so that this pharmaceutical composition ensure that well
Homogeneity, mobility and tabletting produce in mouldability, reach optimum industrial significance.
The pregelatinized Starch mixing of acarbose and good mobility, for improving the mobility of acarbose, thus
Ensure the homogeneity of mixing and the mobility that powder is good；Second step adds microcrystalline Cellulose, it is possible to make acarbose powder divide
It is dispersed in the multi-branched of microcrystalline cellulose crude granule, improves the compressibility of acarbose；3rd step, adds lubricant (as firmly
Ester acid magnesium, hydrogenated vegetable oil) and fluidizer (silicon dioxide, Pulvis Talci), tabletting.
If using conventional adjuvant addition manner to carry out film-making, or do not carry out mixing pressure by method provided by the present invention
Sheet, acarbose poor fluidity, it is difficult to ensure that the homogeneity of mixing, the skeleton function of microcrystalline Cellulose can not be sent out very well simultaneously
Waving, the mixed content of powder uniformity is poor, tabletting produce in mouldability and the hardness of tablet, friability all it is difficult to ensure that,
Do not meet drug quality requirement.
The present invention, through the prescription screening well-chosen to adjuvant, uses stepped mixing powder vertical compression technique to reach product matter
Amount requirement, technique is simple, is suitable for large-scale production.Avoid using wet granulation technology, reduce the disintegrate that medicine causes because of the moisture absorption
Slowly, curative effect of medication is affected；The most also avoid using dry granulation process, reduce loaded down with trivial details preparation technology, and dry granulation is also
It is not suitable for large-scale industrial production.
Detailed description of the invention
Below in conjunction with detailed description of the invention, the invention will be further described.
Example of preparing below with reference to existing document is studied:
Preparation method 1: first acarbose and the silicon dioxide of recipe quantity are added blender and mixes 3 minutes, add crystallite
Cellulose mixes 5 minutes, and the starch and the amylum pregelatinisatum that add recipe quantity mix 5 minutes, are eventually adding the tristearin of recipe quantity
Acid magnesium mixes 1 minute.It is pressed into 2000.
Different preparation technologies is carried out: 1 powder vertical compression, 2 wet granulations, 3 dry granulations according to this prescription.
Preparation method:
Prescription 1: first acarbose and the silicon dioxide of recipe quantity are added blender and mixes 3 minutes, add microcrystalline cellulose
Element mixing 5 minutes, the starch and the amylum pregelatinisatum that add recipe quantity mix 5 minutes, are eventually adding the magnesium stearate of recipe quantity
Mix 1 minute.It is pressed into 2000.
Prescription 2: first acarbose and the silicon dioxide of recipe quantity are added blender and mixes 3 minutes, add microcrystalline cellulose
Element mixing 5 minutes, the starch and the amylum pregelatinisatum that add recipe quantity mix 5 minutes, with the ethanol soft material of 95%.20 mesh sieve systems
Grain, 50 ± 5 DEG C are dried to pellet moisture less than 3%, 20 mesh sieve granulate, and the magnesium stearate being eventually adding recipe quantity mixes 1 minute.
It is pressed into 2000.
Prescription 3: first acarbose and the silicon dioxide of recipe quantity are added blender and mixes 3 minutes, add microcrystalline cellulose
Element mixing 5 minutes, the starch and the amylum pregelatinisatum that add recipe quantity mix 5 minutes, prepare with LGJ-110C dry granulating machine
Granule, 20 mesh sieves are pelletized；LGJ-110C dry granulating machine parameter sets: (squeeze pressure 12.0kgf/cm2, side seal pressure
10.0kgf/cm2, extrusion speed 12.0rpm, feeding speed 10.0rpm, pressure tracking 11.1kgf/cm2.Granulation speed 50rpm,
Chilling temperature 26 DEG C) be eventually adding recipe quantity magnesium stearate mix 1 minute.It is pressed into 2000.
Preparation detects:
| Prescription | Mobility | Hardness | Friability | Disintegration time | Weight differential |
| Prescription 1 | 38.2° | 6.0-7.3kg | 0.49% | 4'05"-4'27" | -12.4%～+9.4% |
| Prescription 2 | 39.3° | 6.0-6.5kg | 0.48% | 5'20"-6'32" | -5.2%～+5.3% |
| Prescription 3 | 39.0° | 6.0-6.6kg | 0.48% | 7'30"-8'00" | -5.1%～+4.4% |
| Acarbose | / | 7.0-8.5kg | / | 4'30"-5'10" | / |
Quality testing:
| Prescription | There is related substance % | * dissolution % | Content % |
| Prescription 1 | 1.1 | 102.9 | 99.8 |
| Prescription 2 | 1.1 | 99.7 | 99.0 |
| Prescription 3 | 1.2 | 101.8 | 99.4 |
* relatively big because of weight differential deviation, choose qualified of weight differential during dissolution detection and detect, it is to avoid because of weight
Difference and cause testing result error.
Result proves: in the case of hardness is close, the hardness of prescription 1 and disintegration time are more preferably.Because acarbose is at water
Middle dissolubility is readily soluble, so the difference of disintegration time can reflect the difference of the stripping curve of product.
But the weight differential of powder vertical compression tabletting is relatively big, do not meet production needs.Need the mobility of prescription 1 is carried out
Adjust.
According to the above results, formulation and technology is adjusted:
Lubricant in prescription, fluidizer carry out the adjustment of consumption, and design prescription is as follows:
| Title | Prescription 4 | Prescription 5 | Prescription 6 | Prescription 7 | Prescription 8 | Prescription 9 |
| Acarbose | 50g | 50g | 50g | 50g | 50g | 50g |
| Pregelatinized Starch | 60g | 60g | 60g | 60g | 60g | 60g |
| Microcrystalline Cellulose | 25g | 25g | 25g | 25g | 25g | 25g |
| Magnesium stearate | 0.1g | 0.1g | 0.1g | 0.1g | 0.1g | 0.1g |
| Silicon dioxide | 0.1g | 0.15g | 0.20g | 0.25 | 0.30 | 0.35 |
| Make | 1000 | 1000 | 1000 | 1000 | 1000 | 1000 |
Technique:
The method of the preparation pharmaceutical composition containing acarbose: first supplementary material is processed: 60 mesh sieves crossed by raw material, and remaining is former auxiliary
80 mesh sieves all crossed by material.Weigh the acarbose of recipe quantity, pregelatinized Starch first to mix 2 minutes, add microcrystalline Cellulose and mix 2 points
Clock.Add remaining adjuvant in prescription, mix 5 minutes.Tabletting.
Preparation detects: weight differential
| Title | Average tablet weight | Maximum tablet weight | Minimum tablet weight | Weight differential |
| Prescription 4 | 135.95mg | 144mg | 128mg | -5.8%～+5.9% |
| Prescription 5 | 135.00mg | 142mg | 127mg | -5.9%～+5.2% |
| Prescription 6 | 136.05mg | 141mg | 130mg | -4.4%～+3.6% |
| Prescription 7 | 137.10mg | 143mg | 132mg | -3.7%～+4.3% |
| Prescription 8 | 135.95mg | 142mg | 130mg | -4.4%～+4.5% |
| Prescription 9 | 134.20mg | 137mg | 130mg | -3.1%～+2.1% |
Mobility: angle of repose
| Title | Angle of repose |
| Prescription 4 | 36.7° |
| Prescription 5 | 35.9° |
| Prescription 6 | 35.1° |
| Prescription 7 | 33.4° |
| Prescription 8 | 32.6° |
| Prescription 9 | 32.6° |
Prescription 9 quality inspection:
Prescription 9 is surveyed content, has related substance, stripping curve and compare with the former acarbose tablet commercially available product ground.
| Prescription | Hardness | Disintegration time | There is related substance % | Dissolution % (water) | Content % |
| Prescription 9 | 8.3-11.7kg | 4'20"-5'30" | 1.1 | 100.3 | 99.9 |
| Commercially available product | 7.0-8.5kg | 4'30"-5'10" | 2.4 | 97.3 | 99.7 |
Prescription 9 and the former acarbose tablet ground are by WS1The dissolution method of-(S-396)-2003Z measures, with water 1000ml
For dissolution medium, 75 revs/min, slurry processes, according to following chromatographic condition mensuration.Result prescription 9 and commercially available product all reach in 15 timesharing
More than 85%, it is believed that both stripping curves are similar.Stripping curve contrast see table.
Prescription 9 and the former acarbose tablet stripping curve measurement result ground
| Time min | 0 | 5 | 10 | 15 | 30 | 45 |
| Prescription 9 (n=6) | / | 60.6 | 93.3 | 98.3 | 100.3 | 100.0 |
| SD | / | 8.3 | 5.6 | 2.5 | 1.2 | 0.8 |
| RSD | / | 13.71% | 5.98% | 2.56% | 1.16% | 0.78% |
| Acarbose (n=2) | / | 47.3 | 84.3 | 98.9 | 97.3 | 99.0 |
| SD | / | 1.53 | 3.82 | 2.59 | 0.51 | 0.69 |
| RSD | / | 3.23% | 4.53% | 2.62% | 0.52% | 0.70% |
Prescription 9 and commercially available product relatively see no significant difference from content and dissolution, have related substance prescription 9 lower, table
Daylight side 9 and acarbose no significant difference.
Compared with product of the present invention has related substance with commercially available product:
Prescription 9 acarbose tablet composes comparative result with commercially available product impurity
The acarbose raw material of product purchasing of the present invention, contained miscellaneous A is high compared with the miscellaneous A of acarbose, causes acarbose tablet impurity A
Relatively commercially available product is high.In raw material, other impurity D, B, C are all low compared with commercially available product, so acarbose tablet impurity D, B, C of the present invention are the most equal
Low compared with commercially available product.Acarbose tablet of the present invention is the most miscellaneous low compared with commercially available product.
Prescription 9 acarbose tablet accelerated test result
Lot number: prescription 9 batch: 50,000 specification: 50mg
Packaging: aluminum-plastic packaged investigation condition: 40 DEG C ± 2 DEG C, RH75% ± 5%
Note: * " meets regulation " and refers to: antibacterial≤1000cfu/g, mycete, yeast≤100cfu/g, escherichia coli must not
Detection
/: do not detect.
Commercially available product accelerated test result
Specification: 50mg
Packaging: aluminum-plastic packaged investigation condition: 40 DEG C ± 2 DEG C, RH75% ± 5%
Proving that the product quality of the present invention is more excellent than commercial preparation, the product prescription composition of the present invention and technique are also full
Foot is big to be produced, and technique is simple.
Compared with the former acarbose tablet commercially available product ground, the product of the present invention is under four kinds of solubility media: water dissolution medium,
Dissolution is contrasted under pH6.8 phosphate buffer dissolution medium, pH4.5 phosphate buffer dissolution medium, 0.1MHCl dissolution medium
The stripping curve f of curve, the product of the present invention and commercially available product2Value is more than 60.The product of the present invention is having in related substance control
Will be apparently higher than the former acarbose tablet commercially available product ground.
Claims (8)
1. Acarbose medicine composition, by weight, including:
Described filler includes microcrystalline Cellulose and pregelatinized Starch.
Acarbose medicine composition the most according to claim 1, it is characterised in that described lubricant is stearic acid
One or more in magnesium, stearic acid or hydrogenated vegetable oil.
Acarbose medicine composition the most according to claim 1, it is characterised in that described fluidizer is silicon dioxide
Or Pulvis Talci.
Acarbose medicine composition the most according to claim 1, it is characterised in that the weight portion of described filler is
1.5-2 part, wherein microcrystalline Cellulose 0.5 part, pregelatinized Starch 1-1.5 part.
Acarbose medicine composition the most according to claim 1, it is characterised in that the weight portion of described filler is
1.6-1.8 part, wherein microcrystalline Cellulose 0.5 part, pregelatinized Starch 1.1-1.3 part.
Acarbose medicine composition the most according to claim 5, it is characterised in that the weight portion of described lubricant is
0.002 part.
Acarbose medicine composition the most according to claim 6, it is characterised in that the weight portion of described fluidizer is
0.007 part.
8. the preparation method of Acarbose medicine composition described in any one of claim 1-7, it uses stepped mixing technique: first
By acarbose with there is the pregelatinized Starch of good fluidity to carry out first order mixing, then carry out the second level with microcrystalline Cellulose and mix
Close, be eventually adding lubricant and fluidizer carries out third level mixing, tabletting.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610675348.XA CN106265702A (en) | 2016-08-16 | 2016-08-16 | Acarbose medicine composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610675348.XA CN106265702A (en) | 2016-08-16 | 2016-08-16 | Acarbose medicine composition and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106265702A true CN106265702A (en) | 2017-01-04 |
Family
ID=57678711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610675348.XA Pending CN106265702A (en) | 2016-08-16 | 2016-08-16 | Acarbose medicine composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106265702A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109452622A (en) * | 2018-11-15 | 2019-03-12 | 江苏康缘药业股份有限公司 | A kind of compound ganoderma conidia powder and preparation method thereof |
| CN111053747A (en) * | 2018-10-17 | 2020-04-24 | 北京福元医药股份有限公司 | Acarbose medicinal preparation |
| CN114053234A (en) * | 2021-12-29 | 2022-02-18 | 江苏省药物研究所有限公司 | Acarbose tablet and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101019874A (en) * | 2007-03-12 | 2007-08-22 | 杭州中美华东制药有限公司 | Acarbose medicine composition and its prepn |
| CN102688252A (en) * | 2012-06-12 | 2012-09-26 | 北京韩美药品有限公司 | Acarbose oral solid preparation composition and preparation method thereof |
-
2016
- 2016-08-16 CN CN201610675348.XA patent/CN106265702A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101019874A (en) * | 2007-03-12 | 2007-08-22 | 杭州中美华东制药有限公司 | Acarbose medicine composition and its prepn |
| CN102688252A (en) * | 2012-06-12 | 2012-09-26 | 北京韩美药品有限公司 | Acarbose oral solid preparation composition and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 奚念朱: "《药剂学》", 30 April 1996 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111053747A (en) * | 2018-10-17 | 2020-04-24 | 北京福元医药股份有限公司 | Acarbose medicinal preparation |
| CN109452622A (en) * | 2018-11-15 | 2019-03-12 | 江苏康缘药业股份有限公司 | A kind of compound ganoderma conidia powder and preparation method thereof |
| CN114053234A (en) * | 2021-12-29 | 2022-02-18 | 江苏省药物研究所有限公司 | Acarbose tablet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104490841B (en) | A kind of Apixaban tablet and preparation method thereof | |
| CN103083278A (en) | Roxithromycin capsule and preparation method thereof | |
| CN106265702A (en) | Acarbose medicine composition and preparation method thereof | |
| CN100484574C (en) | Hydrochloric acid cefetamet pivoxil dispersible tablet and method for preparing the same | |
| CN103027899B (en) | Cephalosporin ester drug particle in non-gel state after meeting water, and preparation method and application of drug particle | |
| CN105147614B (en) | A kind of solid pharmaceutical preparation and preparation method thereof including BIBW 2992MA2 | |
| CN110711181B (en) | Tinidazole tablet and preparation method thereof | |
| CN102302466A (en) | Capecitabine medicinal composition capable of direct powder tableting, and application thereof | |
| CN101612138B (en) | Cefetamet pivoxil hydrochloride capsule and preparation method thereof | |
| CN103550187B (en) | A kind of Cefdinir capsule and preparation method thereof | |
| CN106924237A (en) | A kind of pharmaceutical composition of and Metformin hydrochloride net containing En Gelie | |
| CN104098489A (en) | Micronized glibenclamide and composition thereof | |
| CN114053234A (en) | Acarbose tablet and preparation method thereof | |
| CN103536578B (en) | A kind of Cefixime Capsules and preparation method thereof | |
| CN104739792A (en) | Method for preparing roxithromycin dispersible tablet | |
| US7326427B2 (en) | Tablet composition containing Kampo medicinal extract and its manufacturing process | |
| CN114209666A (en) | Prednisone acetate tablet and preparation method thereof | |
| CN104173310A (en) | Stable amoxicillin tablet composition, as well as preparation method and application thereof | |
| CN103070829A (en) | Medicine composition including pramipexole and active ingredients of medicinal salt and preparation method thereof | |
| CN113230226A (en) | Tinidazole tablet and preparation method thereof | |
| CN100415230C (en) | Dispersion tablets of penicillin V potassium, and its preparing method | |
| CN113456601A (en) | Preparation method of candesartan cilexetil hydrochlorothiazide compound tablet | |
| WO2021258590A1 (en) | APPLICATION OF β-GLUCAN AS ADHESIVE IN PREPARATION OF TABLET OR GRANULE | |
| CN103315971B (en) | Acarbose tablets and preparation method thereof | |
| CN111728946A (en) | Acarbose tablet composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170104 |
|
| RJ01 | Rejection of invention patent application after publication |